Distalmotion Company Profile

Background

Distalmotion, founded in 2013 as a spin-off from the Robotics Lab of the Swiss Federal Institute of Technology in Lausanne (EPFL), is a medical device company headquartered in Lausanne, Switzerland. The company's mission is to simplify robotic surgery, making it more accessible to hospitals, surgeons, and patients worldwide. Distalmotion's primary focus is on developing innovative surgical robotics solutions that integrate seamlessly into existing laparoscopic workflows, thereby enhancing the standard of care in minimally invasive surgery.

Key Strategic Focus

Distalmotion's strategic focus centers on:

• Hybrid Surgical Robotics: Developing the Dexter® robotic surgery system, which combines the benefits of traditional laparoscopy with robotic assistance, allowing surgeons to switch between modalities during procedures.

• Accessibility and Affordability: Designing cost-effective and user-friendly robotic solutions suitable for various clinical settings, including hospitals and ambulatory surgical centers (ASCs).

• Market Expansion: Targeting high-volume procedures such as inguinal hernia repairs, particularly in outpatient settings where over 90% of these surgeries are performed in the U.S.

Financials and Funding

Distalmotion has secured significant funding to support its growth and expansion:

• Series E Financing (January 2022): Raised $90 million, led by Revival Healthcare Capital, with participation from 415 Capital and existing investors.

• Subsequent Financing (April 2023): Secured an additional $150 million, again led by Revival Healthcare Capital, to accelerate FDA approval processes and clinical adoption in the U.S.

The capital is intended to support global commercialization efforts, regulatory submissions, and the scaling of operations.

Pipeline Development

Distalmotion's flagship product, the Dexter® robotic surgery system, has achieved several milestones:

• European CE Mark (December 2020): Authorized for clinical use in Europe.

• First Clinical Use (July 2021): Performed initial procedures, including hysterectomies and general surgeries in Swiss hospitals.

• FDA De Novo Clearance (October 2024): Received authorization for marketing Dexter® in the U.S. for adult inguinal hernia repairs.

The company continues to expand the system's indications and is working on broader applications in minimally invasive surgeries.

Technological Platform and Innovation

Dexter® stands out due to its:

• Hybrid Approach: Allows seamless transition between robotic and laparoscopic techniques within the same procedure.

• Open Platform: Compatible with third-party 3D imaging systems, energy devices, and other laparoscopic instruments.

• User-Centric Design: Enables surgeons to remain in the sterile field with direct patient access, enhancing control and flexibility.

• Single-Use Instruments: Provides fully wristed, single-use instruments that ensure precision and reduce reprocessing requirements.

Leadership Team

Distalmotion's leadership comprises experienced professionals:

• Greg Roche: Chief Executive Officer

• Alex Berthoud: Chief People Officer

• Frank Schulkes: Chief Financial Officer

• Michael Friedrich: Chief Operating Officer

• Sarah Moore: Chief Marketing Officer

• Chris Rabbitt: VP General Manager, US

• Felix Wandel: VP General Manager, EMEA

• Todd Tonsing: VP Global Strategy

The Board of Directors includes:

• Rick Anderson: Chairman of the Board

• Martin Dewhurst: Board Member

• Todd Pope: Board Member

• Heinz Jacqui: Board Member

Leadership Changes

In January 2022, Rick Anderson, Chairman of Revival Healthcare Capital, joined Distalmotion's Board as Chairman, bringing extensive experience to guide the company's strategic direction.

Competitor Profile

Market Insights and Dynamics

The surgical robotics market is experiencing significant growth, driven by advancements in minimally invasive procedures and increasing adoption in outpatient settings.

Competitor Analysis

Key competitors include:

• Intuitive Surgical: Pioneer of the da Vinci Surgical System, holding a dominant market position.

• CMR Surgical: Developer of the Versius robotic system, emphasizing flexibility and cost-effectiveness.

• Medtronic: Introduced the Hugo RAS system, aiming to offer a more flexible and cost-effective solution.

These companies focus on enhancing surgical precision, reducing costs, and expanding the accessibility of robotic-assisted surgeries.

Strategic Collaborations and Partnerships

In January 2024, Distalmotion partnered with Proximie, a global health technology platform, to integrate telepresence, content management, and data-driven insights into the Dexter® system. This collaboration aims to extend surgical excellence globally by facilitating knowledge sharing and improving patient outcomes.

Operational Insights

Distalmotion's strategic considerations include:

• Cost-Effectiveness: Offering a more affordable robotic solution compared to competitors.

• Flexibility: Providing a system that integrates with existing surgical workflows without significant infrastructure changes.

• Market Positioning: Targeting high-volume, outpatient procedures to rapidly expand market share.

Strategic Opportunities and Future Directions

Distalmotion plans to:

• Expand Indications: Broaden the approved uses of Dexter® to include additional surgical procedures.

• Global Commercialization: Accelerate market entry in the U.S. and other regions.

• Technological Advancements: Continue innovating to enhance the functionality and user experience of the Dexter® system.

Contact Information

• Website: www.distalmotion.com

• LinkedIn: Distalmotion

• Twitter: @Distalmotion